Pierre Fabre Pharmaceuticals and Grupo Biotoscana enter into a Commercialization Agreement in the field of Oncology
July 25, 2016
Pierre Fabre Pharmaceuticals, the second-largest French private pharmaceutical laboratory and Grupo Biotoscana SL (GBT), a leading specialty pharmaceutical company in Latin America, today announced that they have completed an agreement in the field of oncology for GBT to commercialize Navelbine® (Vinorelbine) in injectable and oral forms, Javlor® (Vinflunine) and Busilvex® (Busulfan) in Colombia, Chile, Ecuador and Peru. Financial terms of the transaction were not disclosed.
GBT has received exclusive rights to register, import, market, promote and commercialize said pharmaceutical products in the before mentioned territories.
GBT, which is majority-owned by private equity firm Advent International, has operations in 10 Latin American countries, including high-growth geographies such as Argentina, Brazil, Colombia, Chile, Mexico Ecuador and Peru. The company focuses on fast-growing market segments such as specialty care, rare diseases and biopharmaceuticals.
Pierre Fabre Pharmaceuticals’ business in oncology is supported by over 1,000 employees worldwide. In 2015, its global sales in oncology surpassed €200 million on the strength of the Oral Navelbine®, Javlor® and Busilvex® brands. Pierre Fabre Pharmaceuticals dedicates about 50% of its R&D spending to oncology.
This new agreement with GBT will provide South American patients’ access to Pierre Fabre’s unique medicines to treat advanced forms of breast, lung and bladder cancers stated Frédéric Duchesne, CEO of Pierre Fabre Pharmaceuticals. We are confident that GBT - Grupo Biotoscana has the knowledge, experience and commitment to successfully commercialize our products in the region.
Today’s announcement is very exciting as GBT welcomes a new partnership with a leading global pharmaceutical company said Mariano García-Valiño, CEO, GBT – Grupo Biotoscana. Pierre Fabre has a long tradition of research and development in the oncology field and this agreement allows us to add three key products to our oncology and hematology portfolio. We are very eager to bring these medicines to the market to serve the many patients in need.